Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BL-B01D1 as monotherapy and in combinations for advanced liver cancer
CTR20251849Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in liver cancer, sponsored by Biokin Pharmaceutical. Started Jul 2025; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
liver cancer
Beyond the preview
Go deeper on CTR20251849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251849.